Scar Treatment Market Analysis, Size and Growth, 2023
© vijay mishra
According to the study, the global scar treatment market is likely to grow significantly during the forecast period, due to increasing prevalence of skin diseases such as psoriasis, eczema, vitiligo and photoaging of skin, which is increasing due to excessive exposure to pollution and ultraviolet radiation. This further results in sunburns, reduced skin elasticity, and hair loss. Skin diseases are also caused by various other factors, such as excessive alcohol consumption, environmental pollution, and consumption of tobacco. These conditions without proper treatment on time, can lead to the formation of scars. Various other skin problems such as, acne, burns, post-surgical marks, and stretch marks due to pregnancy or changes in body weight can also lead to scar formation. However, side effects of scar treatment products and therapies and high cost associated with scar treatment are some of the key factors restraining the growth of global scar treatment market.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/scar-treatment-market/report-sample
As per the findings of the research, the topical scar treatment is the largest type of scar treatment solution in the global scar treatment market, primarily due to increasing availability of user friendly and non-invasive topical scar treatment solutions. Based on type of scars, post-surgical scar treatment was the largest contributor to the global scar treatment market, in 2016. Hospitals was the largest end user for the global scar treatment, in 2016.
Key player in the scar treatment market are collaborating and acquiring other players to offer more advance solutions for scar treatment. In March 2017, Valeant Pharmaceutical International, Inc. announced the sale of its AcneFree, AMBI and CeraVe skincare brands to L’Oréal for $1.3 billion in cash. The transaction is expected to help the company to repay term loan debt under its senior credit facility.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/scar-treatment-market
Some of the other key players in the global scar treatment market are Smith & Nephew Plc, Syneron Medical Ltd., Mölnlycke Health Care AB, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Beijing Toplaser Technology Company Ltd., Merz GMBH & Co KGAA, Valeant Pharmaceuticals International Inc., Pacific World Corporation, Avita Medical Ltd. Enaltus LLC, Sonoma Pharmaceuticals Inc., CCA Industries Inc., Scarguard Labs LLC, Quantum Health, Hologic Inc.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/scar-treatment-market/report-sample
As per the findings of the research, the topical scar treatment is the largest type of scar treatment solution in the global scar treatment market, primarily due to increasing availability of user friendly and non-invasive topical scar treatment solutions. Based on type of scars, post-surgical scar treatment was the largest contributor to the global scar treatment market, in 2016. Hospitals was the largest end user for the global scar treatment, in 2016.
Key player in the scar treatment market are collaborating and acquiring other players to offer more advance solutions for scar treatment. In March 2017, Valeant Pharmaceutical International, Inc. announced the sale of its AcneFree, AMBI and CeraVe skincare brands to L’Oréal for $1.3 billion in cash. The transaction is expected to help the company to repay term loan debt under its senior credit facility.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/scar-treatment-market
Some of the other key players in the global scar treatment market are Smith & Nephew Plc, Syneron Medical Ltd., Mölnlycke Health Care AB, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Beijing Toplaser Technology Company Ltd., Merz GMBH & Co KGAA, Valeant Pharmaceuticals International Inc., Pacific World Corporation, Avita Medical Ltd. Enaltus LLC, Sonoma Pharmaceuticals Inc., CCA Industries Inc., Scarguard Labs LLC, Quantum Health, Hologic Inc.